XML 41 R30.htm IDEA: XBRL DOCUMENT v3.25.3
Revenue Recognition (Tables)
 9 Months Ended
Sep. 30, 2025
Disaggregation Of Revenue [Line Items]  
Summary of Disaggregation of Revenues
The following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands):
 Three Months Ended
September 30, 2025		Three Months Ended
September 30, 2024
 U.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net     
HEPLISAV-B$89,954 $- $89,954 $79,345 $- $79,345 
Total product revenue, net89,954 - 89,954 79,345 - 79,345 
Other revenue4,739 183 4,922 1,263 22 1,285 
Total revenues$94,693 $183 $94,876 $80,608 $22 $80,630 
Nine Months Ended
September 30, 2025		Nine Months Ended
September 30, 2024
U.S.Non U.S.TotalU.S.Non U.S.Total
Product revenue, net
HEPLISAV-B$245,163 $1,622 $246,785 $195,030 $2,347 $197,377 
Total product revenue, net245,163 1,622 246,785 195,030 2,347 197,377 
Other revenue10,903 794 11,697 7,663 174 7,837 
Total revenues$256,066 $2,416 $258,482 $202,693 $2,521 $205,214 
HEPLISAV-B  
Disaggregation Of Revenue [Line Items]  
Schedule of Revenues from Major Customers
The following table summarizes HEPLISAV-B product revenue from each of our three largest customers (as a percentage of total HEPLISAV-B product revenue):
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2025202420252024
Largest customer33%31%30%29%
Second largest customer21%20%20%21%
Third largest customer21%19%20%18%
Summary of Product Revenue Allowance and Reserve Categories
The following table summarizes balances and activities in HEPLISAV-B product revenue allowance and reserve categories for the nine months ended September 30, 2025 (in thousands):
 
Balance at
Beginning
of Period
Provisions
related to
current
period sales
Credit or
payments
made during
the period
Adjustments (3)
Balance
at End of
Period
Nine months ended September 30, 2025:
Accounts receivable reserves (1)
$9,317 $69,176 $(66,495)$(2)$11,996 
Revenue reserve accruals (2)
$31,479 $46,346 $(42,590)$(11,187)$24,048 
(1)Reserves are for chargebacks, discounts and other fees.
(2)Accruals are for returns, rebates and other fees.
(3)Adjustments for $11.2 million primarily from a change in estimate for product returns.
CpG 1018 adjuvant  
Disaggregation Of Revenue [Line Items]  
Summarizes balances and activities in our contract asset account The following table summarizes balances and activities in our contract asset account (in thousands):
 
Balance at
Beginning
of Period
Additions
Subtractions
Balance
at End of
Period
Nine months ended September 30, 2025
Contract asset, included in other current assets (1)
$351 $10,903 $(8,178)$3,076 
Contract asset, included in other assets (long term) (2)
$71,307 $— $(10,970)$60,337 
(1)The $3.1 million contract asset is derived from our agreement with the DoD.
(2)The Clover contract asset was included in non-current assets to reflect the timing of expected long term demand for CpG 1018 adjuvant for Clover Product. During the nine months ended September 30, 2025, we recorded an allowance for doubtful accounts of approximately $11.0 million relating to the contract asset recognized for Clover. See Note 6 for further discussion.